Biomimetic Stent and Drug Eluting Balloon to Treat Recurrent Cephalic Arch Stenosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-05

Study Completion Date

2021-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study evaluates the use of a biomimetic stent (SUPERA®) and a drug eluting balloon (DEB - Passeo 18 Lux) for the treatment of recurrent and tight cephalic arch stenosis in patients with brachiocephalic fistulas. All participants will undergo angioplasty with stated devices, and be followed up with over 12 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sirolimus Drug-coated Balloon Versus Stent Graft

NCT05938530

Arteriovenous Shunt Thrombosis Blood Vessel Prosthesis

RECRUITING NA

Study on the Safety and Effectiveness of a Biodegradable Patent Foramen Ovale Occluder System

NCT07300358

Cardiovascular Abnormality Heart Defects, Congenital Heart Septal Defects +5 more

NOT_YET_RECRUITING NA

Comparison of the SUpera® PERipheral System in the Superficial Femoral Artery

NCT00933270

Peripheral Vascular Disease

COMPLETED NA

A Study of Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms

NCT07228312

Intracranial Aneurysm

NOT_YET_RECRUITING

Evaluation of the Efficacy and Safety of the Application of BeGraft Peripheral Stent Graft System

NCT04023370

Iliac Artery Stenosis

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To date, the treatment options are limited for recurrent and tight cephalic arch stenosis in patients with brachiocephalic fistulas - Angioplasty, with or without the placement of a stent, surgical bypass using the internal jugular vein or a cephalic/brachial venous anastomosis, or the creation of a new fistula may be a reasonable option. Angioplasty may be associated with technical failure and rupture of the arch vein in reported incidences of 24% and 6%, respectively. Percutaneous Transluminal Angioplasty (PTA) is associated with very low primary patency rates of 42% and 23% at 6 and 12 months, whilst bare stents are equally poor, with reported patency of 39% and 0% at those same time-point. The use of a biomimetic stent (SUPERA®) in the cephalic arch has not been studied to date, but may not only offer protection from rupture of the arch vein but may also create a material barrier to prevent the development of Neo-Intimal Hyperplasia (NIH). With the additional use of drug elution, this may impede NIH effect even more.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brachiocephalic Vein Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

All subjects will be treated with SUPERA® stents and Passeo-18-Lux

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Passeo-18 Lux and SUPERA® stent

Target lesion will be treated with Passeo-18 Lux Drug Eluting Balloon and SUPERA® stent during angioplasty

Group Type EXPERIMENTAL

Passeo-18 Lux and SUPERA® stent

Intervention Type DEVICE

Angioplasty of Arteriovenous Fistula (AVF) performed using Passeo-18 Lux and SUPERA® stent for patients with cephalic arch stenosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Passeo-18 Lux and SUPERA® stent

Angioplasty of Arteriovenous Fistula (AVF) performed using Passeo-18 Lux and SUPERA® stent for patients with cephalic arch stenosis

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient's age is above 21 and below 90
* Informed consent obtained
* Chronic background treatment with daily ASA
* Patients with significant Cephalic Arch Vein Stenosis or recurrent stenosis within 6 months of initial POBA diagnosed either clinically or with Duplex Ultrasound
* Post-angioplasty cephalic arch lumen size between 5mm - 7mm maximum diameter

Exclusion Criteria

* Patients with significant central vein stenosis (\>70%) or total occlusion at time of angiographic study
* Cephalic arch stenosis \<50% stenosis or diameter \>5mm
* Patients with previous cephalic arch stenting (Bare Metal Stents or stent graft)
* Concomitant fistula inflow problem (e.g. juxta-anastomotic) that cannot be corrected optimally during the intervention (\>30% residual stenosis or angiographic lumen \<3mm)
* Patients with minor or major cephalic arch rupture during POBA procedure and the rupture point cannot be adequately sealed off during the procedure requiring a covered stent or open conversion
* Cephalic arch lesion length \<10mm or greater than 10cm
* Patients with uncontrolled hypertension
* Patient \<21 or \> 90 years of age.
* Pregnant women or women of childbearing potential who are not following an effective method of contraception.
* Contraindication to aspirin or clopidogrel usage
* Mental condition rendering the subject unable to understand the nature, scope, and possible consequences o the study, or language barrier such that the subject is unable to give informed consent.
* Uncooperative attitude or potential for non-compliance with the requirements of the protocol making study participation impractical
* Patients who do NOT have impaired renal function
* Occluded or thrombosed fistula
* Patients presenting with central venous stenosis
* Final angioplasty treatment requires a stent or DEB \>7mm in diameter
* Multiple lesions in the access circuit that cannot be treated with one stent and DEB.
* Vascular access circuit placed in the lower extremities
* Bare metal stent or stent-graft placed previously
* Metastatic caner or terminal medical condition
* Blood coagulation disorder
* Limited life expectancy (\<6 months)
* Sepsis or active infection
* Recent arm thrombophlebitis
* Allergy or other known contraindication to iodinated media contrast, heparin or paclitaxel

Minimum Eligible Age

21 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No